Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IIOngoingJul 22, 2026CLEVIPREXLack of Assurance of SterilityChiesi USA, Inc. · D-0689-2026Class IIOngoingJul 22, 2026CAREone, Carbamide Peroxide 6.5%SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).Bell Pharmaceuticals, Inc · D-0688-2026Class IIOngoingJul 22, 2026meijer, Carbamide Peroxide 6.5%SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).Bell Pharmaceuticals, Inc · D-0687-2026Class IIOngoingJul 22, 2026Foster & ThriveSubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).Bell Pharmaceuticals, Inc · D-0686-2026Class IIOngoingJul 22, 2026LEADER, Carbamide Peroxide 6.5%SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).Bell Pharmaceuticals, Inc · D-0685-2026Class IIOngoingJul 22, 2026GOOD NEIGHBOR PHARMACYSubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).Bell Pharmaceuticals, Inc · D-0684-2026Class IIOngoingJul 22, 2026FAMILY WellnessSubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).Bell Pharmaceuticals, Inc · D-0683-2026Class IIOngoingJul 22, 2026AUDIOLOGIST'S CHOICESubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).Bell Pharmaceuticals, Inc · D-0682-2026Class IIOngoingJul 22, 2026TopCare HealthSubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).Bell Pharmaceuticals, Inc · D-0681-2026Class IIOngoingJul 22, 2026QC Quality ChoiceSubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).Bell Pharmaceuticals, Inc · D-0680-2026Class IIOngoingJul 22, 2026Clinere, Carbamide PeroxideSubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).Bell Pharmaceuticals, Inc · D-0679-2026Class IIOngoingJul 22, 2026CVS HealthSubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).Bell Pharmaceuticals, Inc · D-0678-2026Class IIOngoingJul 22, 2026Nystatin Cream USPSubpotent Drug: Low out of specification assay results performed during long-term stability testing.Padagis US LLC · D-0677-2026Class IIOngoingJul 15, 2026Clomiphene Citrate USP Active Pharmaceutical IngredientcGMP deviationsShimoga Chemicals · D-0691-2026Class IIOngoingJul 15, 2026Azacitidine for Injection 100mg/VialLack of Sterility AssuranceReliance Life Sciences Private Limited · D-0674-2026Class IIOngoingJul 15, 2026Bortezomib for Injection 3.5mg/VialLack of Sterility AssuranceReliance Life Sciences Private Limited · D-0673-2026Class IIOngoingJul 15, 2026Pemetrexed for Injection 500mg/VialLack of Sterility AssuranceReliance Life Sciences Private Limited · D-0672-2026Class IIOngoingJul 15, 2026Pemetrexed for Injection 100mg/VialLack of Sterility AssuranceReliance Life Sciences Private Limited · D-0671-2026Class IIOngoingJul 15, 2026Drogueria San Juan Puerto Rico Isopropyl Alcohol 70%Subpotent drugGasco Industrial Corp. · D-0670-2026Class IIOngoingJul 15, 2026Drogueria San Juan Puerto Rico Isopropyl Alcohol 70%Subpotent drugGasco Industrial Corp. · D-0669-2026Class IIOngoingJul 15, 2026Drogueria San Juan Puerto Rico Isopropyl Alcohol 70%Subpotent drugGasco Industrial Corp. · D-0668-2026Class IIOngoingJul 15, 2026Gasco Isopropyl Alcohol 70%Subpotent drugGasco Industrial Corp. · D-0667-2026Class IIOngoingJul 15, 2026Gasco Isopropyl Alcohol 70%Subpotent drugGasco Industrial Corp. · D-0666-2026Class IIOngoingJul 15, 2026Gasco Isopropyl Alcohol 70%Subpotent drugGasco Industrial Corp. · D-0665-2026Class IIOngoingJul 15, 2026Methohexital SodiumFailed Impurities/Degradation SpecificationsQuVa Pharma, Inc. · D-0664-2026Class IIOngoingJul 15, 2026Medline Remedy Specialized Silicone CreamFailed Impurities/Degradation Specifications; Formaldehyde levels exceeded specification.BioMed Laboratories, LLC. · D-0663-2026Class IIOngoingJul 15, 2026Methohexital Sodium for InjectionFailed Impurities/Degradation SpecificationsOnesource Specialty Pharma Limited · D-0662-2026Class IIOngoingJul 8, 2026Glucagon Emergency Kit for Low Blood SugarCGMP deviation: OOS result observed for the Gliding Force functionality test during 12-month long term stability testing.Lupin Pharmaceuticals Inc. · D-0723-2026Class IIOngoingJul 8, 2026Gemcitabine InjectionTemperature Abuse: Product was stored incorrectly in a controlled room temperature environment instead of a refrigerated environment.McKesson · D-0714-2026Class IIOngoingJul 8, 2026Revitaderm Wound CareCGMP Deviations; product manufactured in the same facility under the same conditions as the product found to be contaminatedBlaine Labs Inc · D-0699-2026Class IIOngoingJul 8, 2026Fungal Fusion ERADICATION SolutionCGMP Deviations; the firm discontinued required stability testing for products on the market still within expiryBlaine Labs Inc · D-0698-2026Class IIOngoingJul 8, 2026TERPENICOL Antifungal SolutionCGMP Deviations; the firm discontinued required stability testing for products on the market still within expiryBlaine Labs Inc · D-0697-2026Class IIOngoingJul 8, 2026vite20 Antifungal CreamCGMP Deviations; the firm discontinued required stability testing for products on the market still within expiryBlaine Labs Inc · D-0696-2026Class IIOngoingJul 8, 2026TERPENICOL Antifungal CreamCGMP Deviations; the firm discontinued required stability testing for products on the market still within expiryBlaine Labs Inc · D-0695-2026Class IIOngoingJul 8, 2026TRIPENICOL S Antifungal SolutionCGMP Deviations; the firm discontinued required stability testing for products on the market still within expiryBlaine Labs Inc · D-0694-2026Class IIOngoingJul 8, 2026TRIFLUENT PHARMA TRIDERGEL Wound Care GelCGMP Deviations: product manufactured in the same facility under the same conditions as the product found to be contaminatedBlaine Labs Inc · D-0693-2026Class IOngoingJul 8, 2026Revitaderm Wound Care GelMicrobial contamination of Non-Sterile Product: samples identified the presence of Lysinibacillus fusiformis and other Bacillus sppBlaine Labs Inc · D-0692-2026Class IIOngoingJul 8, 2026Cinacalcet Hydrochloride TabletscGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).Cipla USA, Inc. · D-0676-2026Class IIOngoingJul 8, 2026Cinacalcet Hydrochloride TabletscGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).Cipla USA, Inc. · D-0675-2026Class IIOngoingJul 8, 2026Cinacalcet Hydrochloride TabletscGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).Cipla USA, Inc. · D-0661-2026